Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases
Description
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed) MeSH
Hierarchy View
Subtype Terms (19)
Acid-Base Imbalance
8 drugs (2 approved, 6 experimental)
Bone Diseases, Metabolic
85 drugs (46 approved, 39 experimental)
Calcium Metabolism Disorders
4 approved drugs
DNA Repair-Deficiency Disorders
10 drugs (8 approved, 2 experimental)
Glucose Metabolism Disorders
80 drugs (41 approved, 39 experimental)
Hyperlactatemia
10 drugs (7 approved, 3 experimental)
Iron Metabolism Disorders
9 drugs (6 approved, 3 experimental)
Lipid Metabolism Disorders
37 drugs (17 approved, 20 experimental)
Malabsorption Syndromes
27 drugs (11 approved, 16 experimental)
Metabolic Syndrome
329 drugs (116 approved, 213 experimental)
Metabolism, Inborn Errors
25 drugs (13 approved, 12 experimental)
Mitochondrial Diseases
49 drugs (25 approved, 24 experimental)
Phosphorus Metabolism Disorders
1 approved drug
Porphyrias
9 drugs (8 approved, 1 experimental)
Proteostasis Deficiencies
1 approved drug
Wasting Syndrome
6 approved drugs
Water-Electrolyte Imbalance
6 drugs (4 approved, 2 experimental)
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (20)
Phase 3 Indicated Drugs (19)
Other Experimental Indicated Drugs (73)
Organization Involved with Phase 4 Indications (46)
Organization Involved with Phase 3 Indications (26)
Organization Involved with Phase 2 Indications (70)
Case Western Reserve University
Institut National de la Santé Et de la Recherche Médicale, France
Instituto Mexicano del Seguro Social
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
South-Eastern Norway Regional Health Authority
The University of Texas, Dallas
University of Alabama, Birmingham
Organization Involved with Phase 1 Indications (23)
Organization Involved with Other Experimental Indications (90)
California Strawberry Commission
Centre National d'Etudes Spatiales
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Danish Council for Independent Research
Federal University of Health Science of Porto Alegre
German Diabetes Foundation, Munich, Germany
German Institute of Human Nutrition
Illinois Institute of Technology
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Instituto Venezolano de Investigaciones Cientificas
Institut technique d'études et de recherches des corps gras
Klinikum Ernst von Bergmann Augenklinik Laserzentrum
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Nutrition, Vietnam
National University of Singapore
Satakunta Sea Buckthorn Society
Steno Diabetes Center Copenhagen
Swiss Federal Institute of Technology
Translational Research Institute for Metabolism and Diabetes, Florida
Universidade Estadual de Londrina
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
